India

Reimbursed Care Access

India maintains a restrictive legal regime for classical psychedelics under its national drug-control framework (NDPS Act), so most psilocybin-class, tryptamine, phenethylamine and related compounds have no authorised medical use outside of sanctioned clinical research and are actively policed. Ketamine is widely available and used for anesthesia and is provided off‑label in private clinics for psychiatric indications (generally not reimbursed by public insurance); esketamine (Spravato) is not established as a reimbursed or widely marketed therapy in India.